TriMaximize: A Multicentre, Prospective, Non-interventional Trial in Asthma Patients

This observational study (no experimental treatment) follows asthma patients who are starting a triple inhaler therapy combining three medications: an inhaled steroid, a long-acting bronchodilator, and a long-acting muscarinic antagonist (brand name Trimbow). The goal is to track real-world safety and effectiveness of this combination in everyday clinical practice. **You may be eligible if:** - You are 18 or older - You have a confirmed diagnosis of asthma, with or without COPD - Your doctor has independently decided to prescribe triple inhaler therapy (ICS/LABA/LAMA) for you - You are willing to share your de-identified medical data for the study **You may NOT be eligible if:** - You have participated in an interventional (experimental) clinical trial within the past 30 days - You plan to join another interventional trial during the study period Talk to your doctor to see if this trial is right for you.